Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis
LUTS: Lower Urinary Tract Symptoms · 2018-01 · 10 (1) · 84-92
DOI: 10.1111/luts.12144 ↗Abstract
Objectives We carried out a systematic review and meta‐analysis to assess tadalafil 5 mg once‐daily for the treatment of lower urinary tract symptoms ( LUTS ) and erectile dysfunction ( ED ). Methods A literature review was performed to identify all published randomized double‐blind, placebo‐controlled trials of tadalafil 5 mg once‐daily for the treatment of LUTS and ED . The search included the following databases: MEDLINE , EMBASE , and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Results Thirteen publications involving a total of 3973 patients were used in the analysis, including 13 RCTs that compared tadalafil 5 mg once‐daily with placebo. We found that tadalafil 5 mg once‐daily was effective in improving LUTS suggestive of BPH and treating ED over 12 weeks in our meta‐analysis. Total International Prostate Symptom Score ( IPSS ) ( SMD = − 2.02, 95% CI = − 2.52 to −1.53, P < 0.00001); Benign Prostatic Hyperplasia Impact Index ( BPH‐II ) ( SMD = −0.58, 95% CI = −0.84 to −0.33, P < 0.00001); International Index of Erectile Function‐erectile function ( IIEF ) domain (standardized mean difference [ SMD ] = 5.18, 95% confidence interval [ CI ] = 4.13–6.23, P < 0.00001) indicated that tadalafil 5 mg once‐daily was more effective than the placebo. Safety assessments included discontinuations due to adverse event (odds ratio ( OR ) = 1.79, 95% CI = 1.12–2.85, P = 0.01) indicated that tadalafil 5 mg once‐daily was well tolerated. Conclusions This meta‐analysis indicates that tadalafil 5 mg once‐daily to be an effective treatment for LUTS and ED with a low occurrence of side effects.
EUVIMED